Please login to the form below

Not currently logged in
Email:
Password:

ShangPharma hires Biogen exec

Art Taveras joins as chief scientific officer 

ShangPharma, Art Taveras ShangPharma has hired Biogen Idec's Dr Art Taveras as president and chief scientific officer.

Dr Taveras held several vice president roles at US-based biotech Biogen, including for small molecules drug discovery, chemistry R&D and CMC development.

He now moves to China to head science at ShangPharma, a clinical research organisation (CRO) which employs 2,000 scientists.

"His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies,” said Michael Hui, chairman and CEO of ShangPharma.

Dr Taveras' career prior to joining Biogen includes senior positions at Alantos Pharmaceuticals and Schering-Plough.

28th October 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics